SERETIS, Charalampos, SERETIS, Fotios, GEMENETZIS, George, LIAKOS, Nikolaos, PAPPAS, Apostolos, GOURGIOTIS, Stavros, LAGOUDIANAKIS, E., KERAMIDARIS, D. und SALEMIS, N., 2025. Calcium channel blockers and esophageal sclerosis: should we expect exacerbation of interstitial lung disease?. Freiburg: Universität.
Elsevier - Harvard (with titles)Seretis, C., Seretis, F., Gemenetzis, G., Liakos, N., Pappas, A., Gourgiotis, S., Lagoudianakis, E., Keramidaris, D., Salemis, N., 2025. Calcium channel blockers and esophageal sclerosis: should we expect exacerbation of interstitial lung disease?. Universität, Freiburg. https://doi.org/10.1159/000336584
American Psychological Association 7th editionSeretis, C., Seretis, F., Gemenetzis, G., Liakos, N., Pappas, A., Gourgiotis, S., Lagoudianakis, E., Keramidaris, D., & Salemis, N. (ca. 2025). Calcium channel blockers and esophageal sclerosis: should we expect exacerbation of interstitial lung disease? [Cd]. Universität. https://doi.org/10.1159/000336584
Springer - Basic (author-date)Seretis C, Seretis F, Gemenetzis G, Liakos N, Pappas A, Gourgiotis S, Lagoudianakis E, Keramidaris D, Salemis N (2025) Calcium channel blockers and esophageal sclerosis: should we expect exacerbation of interstitial lung disease?. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Seretis, Charalampos/ Seretis, Fotios/ Gemenetzis, George/ Liakos, Nikolaos/ Pappas, Apostolos/ Gourgiotis, Stavros/ Lagoudianakis, E./ Keramidaris, D./ Salemis, N., Calcium channel blockers and esophageal sclerosis: should we expect exacerbation of interstitial lung disease?, Freiburg 2025.